These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 35869742)

  • 1. New approaches to targeting epigenetic regulation in prostate cancer.
    Thompson D; Choo N; Bolton DM; Lawrentschuk N; Risbridger GP; Lawrence MG; Taylor RA
    Curr Opin Urol; 2022 Sep; 32(5):472-480. PubMed ID: 35869742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-targeting BET, CBP, and p300 inhibits neuroendocrine signalling in androgen receptor-null prostate cancer.
    Choo N; Keerthikumar S; Ramm S; Ashikari D; Teng L; Niranjan B; Hedwards S; Porter LH; Goode DL; Simpson KJ; Taylor RA; Risbridger GP; Lawrence MG
    J Pathol; 2024 Jun; 263(2):242-256. PubMed ID: 38578195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BET bromodomain inhibitors--a novel epigenetic approach in castration-resistant prostate cancer.
    Lochrin SE; Price DK; Figg WD
    Cancer Biol Ther; 2014; 15(12):1583-5. PubMed ID: 25535892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plk1 Inhibition Enhances the Efficacy of BET Epigenetic Reader Blockade in Castration-Resistant Prostate Cancer.
    Mao F; Li J; Luo Q; Wang R; Kong Y; Carlock C; Liu Z; Elzey BD; Liu X
    Mol Cancer Ther; 2018 Jul; 17(7):1554-1565. PubMed ID: 29716963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the BRD4-HOXB13 Coregulated Transcriptional Networks with Bromodomain-Kinase Inhibitors to Suppress Metastatic Castration-Resistant Prostate Cancer.
    Nerlakanti N; Yao J; Nguyen DT; Patel AK; Eroshkin AM; Lawrence HR; Ayaz M; Kuenzi BM; Agarwal N; Chen Y; Gunawan S; Karim RM; Berndt N; Puskas J; Magliocco AM; Coppola D; Dhillon J; Zhang J; Shymalagovindarajan S; Rix U; Kim Y; Perera R; Lawrence NJ; Schonbrunn E; Mahajan K
    Mol Cancer Ther; 2018 Dec; 17(12):2796-2810. PubMed ID: 30242092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BET inhibitors in metastatic prostate cancer: therapeutic implications and rational drug combinations.
    Markowski MC; De Marzo AM; Antonarakis ES
    Expert Opin Investig Drugs; 2017 Dec; 26(12):1391-1397. PubMed ID: 29032717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer.
    Asangani IA; Dommeti VL; Wang X; Malik R; Cieslik M; Yang R; Escara-Wilke J; Wilder-Romans K; Dhanireddy S; Engelke C; Iyer MK; Jing X; Wu YM; Cao X; Qin ZS; Wang S; Feng FY; Chinnaiyan AM
    Nature; 2014 Jun; 510(7504):278-82. PubMed ID: 24759320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRD4 regulates key transcription factors that drive epithelial-mesenchymal transition in castration-resistant prostate cancer.
    Shafran JS; Jafari N; Casey AN; Győrffy B; Denis GV
    Prostate Cancer Prostatic Dis; 2021 Mar; 24(1):268-277. PubMed ID: 32690869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent Advances in Epigenetic Biomarkers and Epigenetic Targeting in Prostate Cancer.
    Kumaraswamy A; Welker Leng KR; Westbrook TC; Yates JA; Zhao SG; Evans CP; Feng FY; Morgan TM; Alumkal JJ
    Eur Urol; 2021 Jul; 80(1):71-81. PubMed ID: 33785255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer.
    Xiao L; Tien JC; Vo J; Tan M; Parolia A; Zhang Y; Wang L; Qiao Y; Shukla S; Wang X; Zheng H; Su F; Jing X; Luo E; Delekta A; Juckette KM; Xu A; Cao X; Alva AS; Kim Y; MacLeod AR; Chinnaiyan AM
    Cancer Res; 2018 Oct; 78(20):5731-5740. PubMed ID: 30135193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours.
    Lasko LM; Jakob CG; Edalji RP; Qiu W; Montgomery D; Digiammarino EL; Hansen TM; Risi RM; Frey R; Manaves V; Shaw B; Algire M; Hessler P; Lam LT; Uziel T; Faivre E; Ferguson D; Buchanan FG; Martin RL; Torrent M; Chiang GG; Karukurichi K; Langston JW; Weinert BT; Choudhary C; de Vries P; Van Drie JH; McElligott D; Kesicki E; Marmorstein R; Sun C; Cole PA; Rosenberg SH; Michaelides MR; Lai A; Bromberg KD
    Nature; 2017 Oct; 550(7674):128-132. PubMed ID: 28953875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic Targeting of the CBP/p300 Bromodomain Blocks the Growth of Castration-Resistant Prostate Cancer.
    Jin L; Garcia J; Chan E; de la Cruz C; Segal E; Merchant M; Kharbanda S; Raisner R; Haverty PM; Modrusan Z; Ly J; Choo E; Kaufman S; Beresini MH; Romero FA; Magnuson S; Gascoigne KE
    Cancer Res; 2017 Oct; 77(20):5564-5575. PubMed ID: 28819026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic regulation of androgen dependent and independent prostate cancer.
    Mishra J; Chakraborty S; Nandi P; Manna S; Baral T; Niharika ; Roy A; Mishra P; Patra SK
    Adv Cancer Res; 2024; 161():223-320. PubMed ID: 39032951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining EZH2 and HDAC inhibitors to target castration-resistant prostate cancers.
    Coulter JB; Easwaran H
    PLoS Biol; 2023 Apr; 21(4):e3002081. PubMed ID: 37104249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of protein kinase C-related kinase (PRK) signalling by the TPα and TPβ isoforms of the human thromboxane A
    O'Sullivan AG; Mulvaney EP; Kinsella BT
    Biochim Biophys Acta Mol Basis Dis; 2017 Apr; 1863(4):838-856. PubMed ID: 28108419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemistry-based assessment of androgen receptor status and the AR-null phenotype in metastatic castrate resistant prostate cancer.
    Gupta S; Vanderbilt C; Abida W; Fine SW; Tickoo SK; Al-Ahmadie HA; Chen YB; Sirintrapun SJ; Chadalavada K; Nanjangud GJ; Bialik A; Morris MJ; Scher HI; Ladanyi M; Reuter VE; Gopalan A
    Prostate Cancer Prostatic Dis; 2020 Sep; 23(3):507-516. PubMed ID: 32094488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen receptor enhancer amplification in matched patient-derived xenografts of primary and castrate-resistant prostate cancer.
    Porter LH; Bakshi A; Pook D; Clark A; Clouston D; Kourambas J; ; Goode DL; Risbridger GP; Taylor RA; Lawrence MG
    J Pathol; 2021 Jun; 254(2):121-134. PubMed ID: 33620092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia.
    Dobosy JR; Roberts JL; Fu VX; Jarrard DF
    J Urol; 2007 Mar; 177(3):822-31. PubMed ID: 17296351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The heterogeneity of prostate cancers lacking AR activity will require diverse treatment approaches.
    Labrecque MP; Alumkal JJ; Coleman IM; Nelson PS; Morrissey C
    Endocr Relat Cancer; 2021 Jul; 28(8):T51-T66. PubMed ID: 33792558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer.
    Faivre EJ; McDaniel KF; Albert DH; Mantena SR; Plotnik JP; Wilcox D; Zhang L; Bui MH; Sheppard GS; Wang L; Sehgal V; Lin X; Huang X; Lu X; Uziel T; Hessler P; Lam LT; Bellin RJ; Mehta G; Fidanze S; Pratt JK; Liu D; Hasvold LA; Sun C; Panchal SC; Nicolette JJ; Fossey SL; Park CH; Longenecker K; Bigelow L; Torrent M; Rosenberg SH; Kati WM; Shen Y
    Nature; 2020 Feb; 578(7794):306-310. PubMed ID: 31969702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.